Alyeska Investment Group, L.P. X4 Pharmaceuticals, Inc Transaction History

Alyeska Investment Group, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$5.41 - $7.4 $2,894 - $3,959	-535 Reduced 0.79%	66,888 $430,000
Q2 2020 Aug 14, 2020	SELL	$7.98 - $10.44 $873,642 - $1.14 Million	-109,479 Reduced 61.89%	67,423 $628,000
Q1 2020 May 15, 2020	SELL	$6.03 - $11.01 $67,487 - $123,223	-11,192 Reduced 5.95%	176,902 $1.77 Million
Q4 2019 Feb 14, 2020	BUY	$9.93 - $14.33 $1.87 Million - $2.7 Million	188,094 New	188,094 $2.01 Million

99.6M

421K

80.6K

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $32.3M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.